eligibility_summary
Eligible: HIV+ adults (>=18) with LP-confirmed B-cell NHL with CSF/CNS involvement or high CNS-IPI (4-6), plasmablastic, gamma-herpesvirus+ tumor, or KS, measurable/evaluable disease, ECOG <=4, adequate organs, HBV suppressed, on/agree to ART, POMALYST REMS, contraception, aspirin, limited prior therapy only. Exclude: other trials/prohibited drugs, allergy, parenchymal brain lymphoma, EF<40%, G3-4 neuropathy, major cardiac/illness, procoagulant disorders, pregnant/nursing.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I trial in HIV-associated B‑cell NHL (DLBCL, BL, plasmablastic). Interventions: pomalidomide (oral immunomodulatory drug, IMiD) plus DA‑EPOCH chemotherapy with optional rituximab for CD20+ tumors. Mechanisms: pomalidomide binds cereblon E3 ligase to degrade IKZF1/3, enhancing T- and NK‑cell activation, reversing T‑cell senescence, modulating cytokines, and upregulating immune markers (notably in EBV+ tumors), DA‑EPOCH components—etoposide (topoisomerase II inhibitor), doxorubicin (anthracycline, DNA intercalation/topo II/ROS), vincristine (microtubule inhibitor), cyclophosphamide (DNA alkylator), prednisone (glucocorticoid inducing lymphoid apoptosis), rituximab (anti‑CD20 mAb, CDC/ADCC). Targets/pathways: malignant B cells (including EBV+), CD20, DNA replication/repair, microtubules, glucocorticoid signaling, and the cereblon‑IKZF immune axis.